chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Approximately 9 days after receiving his third Covid vaccine the patient developed a viral syndrome including fever/chills, muscle aches and fatigue.  This lasted for 1 to 2 days and improved.  Approximately 1 week after that he woke up 1 morning with sudden moderate to severe numbness and tingling in his bilateral hands and feet.  He reports his hands initially felt somewhat heavy as well.  Since the onset the symptoms have been fairly constant but mildly improved.  No ascending progression, vision changes, weakness or trouble breathing.
Chills and fever, fast heartbeat, headache, body aches, syncope, projectile vomiting, nausea, intense stomach ache, tiredness.
burning sensation up to the back of the neck and scalp and part of the feet and leg area on the left side; burning sensation at the injection site in the left arm; This is a spontaneous report from a contactable consumer (patient). A 41-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number; ER8734), via an unspecified route of administration, Left arm on 02Apr2021 at 14:00 (at the age of 41-years-old), as 1ST DOSE, SINGLE for COVID-19 immunization. Medical history included ongoing heart problem (all of his life). The patient was not receiving concomitant medications. The vaccine was administered at pharmacy. No other vaccine was administered on the same day as COVID-19 vaccine. On an unspecified date in Apr2021, 2 or 3 days after the vaccine, the patient had a burning sensation. Has started in more places, so has gotten worse. It first started at the injection site in the left arm, then up to the back of the neck and scalp and part of the feet and leg area on the left side. Therapeutic measures taken as a result of the events included Advil, but it hasn't been working. The events resulted in physician's office visit, the patient went to the doctor on 29Apr2021. The outcome of the events was not recovered.   No follow-up attempts are needed. No further information is expected.
ETD: March 3, 2022, 3rd pregnancy, 1st born was early by 7 weeks cause of IUGR Reversal of Diastolic flow. 12/31/2021 Possible Laryngitis when I woke, didn't think much of it because I talk to a lot of people. 01/01/2022 I had a Runny nose, cough, no fever, fatigue and notice other family members also showed some symptoms. 01/02/2022 Got a PCR Covid test and was positive. 01/03/2022 Was the day I received notice that I had Covid and I immediately called my OB and thru telehealth discussed it. Advised to get pulse Oxy meter, do spot checks, drink plenty of water, Tylenol etc.
Information has been received from a registered nurse concerning a "17 year old" female with no pertinent medical history who on 15-FEB-2011 was vaccinated with the first dose of GARDASIL (lot # 666931/0337Z). Concomitant therapy included ZITHROMAX (reported as "VITHROMAX"). On 15-FEB-2011 the patient was feeling dizzy. The patient was not given treatment. No lab diagnostics studies performed. The patient did not seek medical attention. On an unspecified date, the patient recovered from dizzy. Follow up information has been received from a registered nurse concerning the 16 year old (previously reported as "17 year old") female student with allergy to ZITHROMAX and no illness at time of vaccination, and no adverse event following prior to vaccination who 14-FEB-2011 (previously reported as "15-FEB-2011") was vaccinated with the first dose of GARDASIL in left deltoid. The patient's mother stated that on the evening of 14-FEB-2011 the patient became very dizzy which continued to the morning of the second day. The mother notified the office 24 hours post dose given. On 15-FEB-2011, the patient recovered. Additional information is not expected.
On 06/28/2018 two different Meningococcal/BEXSERO shots were given. One in each arm. On 06/29/2018 around 11:45 a.m. my child's right hand started curling up towards her chest and she then became unresponsive for what seemed like several minutes but probably a minute at the most. She regained consciousness and did not remember anything that happened during the twitching and black out. She was rushed to the ER and several tests were done. CT Scan, lab work, chest Xrays, 2 rounds of Saline IV. All tests were negative and the only explanation was an adverse reaction to the vaccinations and fainting. The pediatrician was called. To say the least he was baffled and stated "He never heard of anything like that ever happening ". The ER physician advised us to follow up with her pediatrician.
Information has been received from a medical assistant referring to a 4 month old male patient. No relevant medical history or concurrent conditions were reported. On 02-JUN-2015, the patient was inadvertently vaccinated with improperly stored ROTATEQ (lot # K014826, expiration date 28-MAY-2016; dose was not reported) orally. No adverse effects were reported. This is one of several reports received from the same reporter. Original report is MARRS#1507USA011322. Additional information has been requested.
Neuropsychiatric; OCD; Crying; Withholding food; Headbanging the same she has had after infections; This is a spontaneous report from a contactable consumer, the patient. A 15-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0181), via an unspecified route of administration on 17Jun2021 at 14:00 (at the age of 15-years-old), as a single dose for COVID-19 immunisation. Medical history included postural orthostatic tachycardia syndrome, paediatric acute onset neuropsychiatric syndrome and mast cell activation syndrome. The patient had known allergies to red dye. Concomitant medications included ivabradine hydrochloride (CORLANOR), pyridostigmine bromide (MESTINON), cromoglicate sodium (GASTROCROM), escitalopram oxalate (LEXAPRO) and clonidine (MANUFACTURER UNKNOWN); all from unknown dates for unknown indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0180), via an unspecified route of administration on 27May2021 at 14:00 (at the age of 14-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Jun2021 at 20:00, the patient experienced neuropsychiatric, obsessive-compulsive disorder (OCD), crying, withholding food and headbanging, the same she has had after infections. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with NSAIDS and antihistamines. The clinical outcome of the events neuropsychiatric, obsessive-compulsive disorder (OCD), crying, withholding food and headbanging were resolving at the time of this report.
This case described the occurrence of an allergic reaction in a 52 year old female pt who received hep B vaccine for prophylaxis. This report was received from the pt, who is an emergency medical technician. The pt's past medical history included allergy to thimerosal. The pt stated that she had unspecified adverse experiences following receipt of previous, unspecified immunizations. On an unspecified date in 2002 the pt received the 1st dose of hep B vaccine. At an unknown time post-immunization, the pt experienced an allergic reaction characterized by mouth sores and a sore throat. The pt was seen by a physician. The events resolved after an unspecified period of time. The hep B immunization series was discontinued.
Chest pain; back pain; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (Chest pain) and BACK PAIN (back pain) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     No medical history was reported by the reporter.  Concomitant products included DILTIAZEM, PHENYTOIN (DILANTIN [PHENYTOIN]), PHENOBARBITAL (FENOBARB), SOTALOL, LEVOTHYROXINE and WARFARIN for an unknown indication.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced CHEST PAIN (Chest pain) and BACK PAIN (back pain). On 17-Feb-2021, CHEST PAIN (Chest pain) and BACK PAIN (back pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details was not reported by the reporter.
?Moderna COVID-19 Vaccine EUA? Syncopy/ Tachycardia/ Bradycardia/ POSSIBLE LEFT ATRIAL ENLARGEMENT/ Iron Deficiency Anemia/ partial small bowel obstruction/ gastritis/ Hives, Shingles/ Coarse tremors/  transient global amnesia/ Occipital neuralgia/ Nystagmus/persistent irritability/  Cervical spinal stenosis /  dyspnea on exertion/ fatigue/ Shortness of breath/ Chills/ Nausea with vomiting/ cool, pale skin/Moderate to severe tendinosis of the supraspinatus and mild to moderate grade tendinosis of the infraspinatus tendons left shoulder/ Occipital neuralgia/ Mild central canal stenosis/ Abnormal labatory results of unknown orgion   Multiple physician visits/ hospital stay/ Emergancy room visits/ Surgeries/ loss of work from 03/21/2021 to present
This spontaneous report was received from the office manager referring to a patient of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant medication. On 14-FEB-2019 the patient was inadvertently administered M-M-R II (rHA) lot number R025335 and expiration date of 06-APR-2020 and lot number R001659 with expiration date of 17-JAN-2020 for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported). No adverse effects were reported. The vaccine was exposed to a temperature excursion of 60°F for 60 minutes while the sterile water diluent did not undergo a temperature excursion. There was no previous temperature excursion. A "data logger" was involved.; Sender's Comments: US-009507513-1902USA011926: US-009507513-1902USA011925: US-009507513-1902USA011924: US-009507513-1902USA007818: US-009507513-1902USA011923.
Muscle spasm and cramps in both hands. Redness at & around administration site. (L) neck pain. Nausea. Weakness (generalized). Headache, body aches, jt pains.
Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jun-2021 at 11:00 AM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.). On 09-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Expired Moderna Covid-19 vaccine administered to patient. More than 12 hours after vial has been punctured.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was provided.  No treatment drug details was included.
Patient was accidently gave moderna covid-19 pediatric dose (age 6 months through5 y) instead of an adult.
Patient  was given the Moderna bivalent booster dose and she should have received the first primary dose of Moderna.
Lower backache; Low grade fever; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Lower backache) and PYREXIA (Low grade fever) in an 85-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetic.   On 05-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced BACK PAIN (Lower backache) and PYREXIA (Low grade fever). At the time of the report, BACK PAIN (Lower backache) and PYREXIA (Low grade fever) outcome was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested
I was pregnant at the time of first dose, and I also received the second dose of the Moderna vaccine from local County Public Health on April 1, 2021. I was pregnant for the second dose as well. My reaction after the second dose of the Moderna COVID-19 vaccine was very severe. I felt like I had the worst case of the flu of my life. I had a fever, vomited and was severely achy and shivering for over 36 hours. I missed work the next day. The adverse event I did not realize until later. When I was about to enter the third trimester I noticed a lump in my right breast. I told my OB-GYN (Dr. at The Women's Clinic) and he said it was likely breast changes due to being pregnant at the time. The lump continued to grow larger. I delivered my healthy daughter via cesarean section on November 9, 2021. In recovery I was telling the nurses about my right breast and that it seemed to be difficult for my daughter to nurse on. The nurses immediately became worried. An ultrasound of my breast was ordered. After I was discharged from the hospital on November 11, 2021 I was told to immediately go to the breast diagnostic center. A mammogram of both breasts was performed. The right breast where the lump was was biopsied. On November 15, 2021 I received the call that I had Stage 3 cancer. I would eventually find out that the cancer had spread to my lymph nodes on my right side. I have undergone 12 infusions of Taxol (3 Taxol, and 9 Abraxane due to adverse reaction to Taxol). I had a double mastectomy (left side was prophylactic) with lymph node dissection on April 7, 2022. I was found to have residual cancer in lymph and original tumor so I will be undergoing 4 rounds of AC chemo, followed by at least 30 rounds of radiation. Followed by additional chemo and hormone blocker medication. I have no family history of breast cancer. I also did genetic testing and tested negative for all cancer genes. I breastfed my first child for a full year. There is no logical explanation for why breast cancer started to develop during pregnancy. I have come to the conclusion that the COVID-19 vaccine I received while pregnant caused my breast cancer/tumor to start growing. I had a completely healthy pregnancy beyond the tumor that started growing in my right breast after receiving the vaccine. My oncologist estimates that the tumor started growing about 6 months before I was diagnosed with breast cancer, which puts it about the date shortly after I received the first COVID-19 vaccine dose. Additionally, after surgery the tumor was found to have Invasive Micro-papillary Carcinoma, which is a very rare form of breast cancer.
severe pain across the top of her breast; This spontaneous case was reported by a consumer and describes the occurrence of BREAST PAIN (severe pain across the top of her breast) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, the patient experienced BREAST PAIN (severe pain across the top of her breast). At the time of the report, BREAST PAIN (severe pain across the top of her breast) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information not provided. Concomitant medications included. medicine for blood pressure, cholesterol and diabetes.
Had PNU on 12/10/08 arm red from site of injection to elbow, took TYLENOL today in am, no relief as of yet (350pm) sleeping off and on all day due to restlessness night. Informed to apply cool compresses and to call her doctor. Phd 12/12/2008 942/ PH disconnected
Patient said it started the following day after the shot and that there was a raised red area of site the size of a quarter. The rash progressed and got worse. Patient went to physician and it was diagnosed as cellulitis.
Information has been received from a licensed practical nurse referring to an unspecified number of patients of unknown age and gender. On unspecified dates, an unspecified number of patients were administered dose of VAQTA (dose, frequency, route and lot# were not reported), which were exposed to a temperature excursion. No adverse experience had been reported. This is one of several reports received from same reporter. Additional information has been requested.
Tired, achy, swollen glands at base of  head and under right ear, metallic taste in mouth
Bells Palsy - Paralysis of left facial muscles - difficulty smiling & blinking  with left side.  No treatment.  Spontaneous  recovery started 12 day after onset.  Muscle weakness continues.
This case was reported by a consumer via call center representative and described the occurrence of erythematous rash in a elderly male patient who received SHINGRIX for prophylaxis. Previously administered products included ZOSTAVAX (received about 10 years before the date of reporting). On an unknown date, the patient received the 1st dose of SHINGRIX (intramuscular). On an unknown date, 1 day after receiving SHINGRIX, the patient experienced erythematous rash and skin blotches. SHINGRIX was continued with no change. On an unknown date, the outcome of the erythematous rash and skin blotches were recovered/resolved. It was unknown if the reporter considered the erythematous rash and skin blotches to be related to SHINGRIX. Additional details were provided as follows: This case was reported by the reporter for her husband. The pharmacy where they received the vaccine is onsite at the physician office. The age at vaccination was not reported. About 2 and a half months before the date of reporting, at 10:00 o clock, the patient received SHINGRIX. Twenty four hours after vaccination, the patient developed minor red blotchy bumps that never headed on his the front of his belly. The reporter stated that they did not go around his side or to his back just on the front. The event lasted for about a week but he never saw or reported it to a physician. This case has been linked with US2018141994, reported by the same reporter.
Developed 5 pox blisters/spots 11 days after vaccination. No other symptoms i.e. fever. Site of injection is itchy as of today.
BAD HEAD ACHE, STUFFYNESS, CHEST CONGEST. TIREDNESS, GRUMPY AS HELL
She had sore arm, fever, chills, bad headache, her arm was really hot.; She had sore arm, fever, chills, bad headache, her arm was really hot.; She had sore arm, fever, chills, bad headache, her arm was really hot/When she takes a deep breath she feels a weird chill; She had sore arm, fever, chills, bad headache, her arm was really hot.; She had sore arm, fever, chills, bad headache, her arm was really hot.; This is a spontaneous report from a Pfizer-sponsored program  non-contactable consumer or other non hcp (patient). A female patient of an unspecified age received BNT162b2 (CONMINTARY, Solution for injection, Lot No: was not reported), via an unspecified route of administration on 15Mar2021 as 1st dose, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported.  The patient experienced she had sore arm, fever, chills, bad headache, her arm was really hot. (pain in extremity), she had sore arm, fever, chills, bad headache, her arm was really hot. (pyrexia), she had sore arm, fever, chills, bad headache, her arm was really hot/when she takes a deep breath she feels a weird chill (chills), she had sore arm, fever, chills, bad headache, her arm was really hot. (headache), she had sore arm, fever, chills, bad headache, her arm was really hot. (feeling hot) on an unspecified date. Medical Information were any unaddressed medical questions referred or forwarded to Medical Information was no.Outcome of the events was recovered.    No follow-up attempts are possible; information about lot/batch number cannot been obtained.
(L) arm pain with area & erythema area tender upon palpation & warm. Diag. cellulitis s/p vaccine admin.
Information has been received from a pharmacist concerning a 62 year old female who on 25-OCT-2006 was vaccinated with Pneumovax 23 (Lot #654981/0674F). The patient called in to the clinic on 27-OCT-2006, with complications. On 27-OCT-2006, the symptoms were fever of 102, warm, red area 4 centimeters (cm) in diameter at injection site and headache. The headache did not respond to ibuprofen or TYLENOL. The patient was referred to the emergency room but never followed through. It was unknown how soon after vaccination the symptoms of fever, injection site warmth, redness and headache occurred. The patient sought unspecified medical attention. At the time of the report the patient's current state was unknown. A lot check was requested. The records of testing prior to release of the lot in question have been rechecked and found to be satisfactory. The lot complies with the standards of the government and was released. Additional information has been requested.
Initial report received on 29 September 2011 from the Investigator participating in the post-marketing observational surveillance study under the reference number M5A16. A case of pertussis disease in a three year old male subject was identified by the investigator based on review of data from the Electronic Disease Surveillance System electronic database. The subject's vaccine history included 4 doses of DAPTACEL; lot number C2749BA received on 21 September 2007, lot number C2797AA received on 26 November 2007, lot number C2800AA received on 22 January 2008, and lot number C2956AA received on 29 October 2008 (routes and sites of administration not reported). The subject developed a cough on 14 July 2011, approximately 33 months after the last dose. On 21 July 2011, the subject developed a paroxysmal cough without a whoop. The subject also experienced posttussive vomiting, apnea and sleep disturbance. Laboratory testing included positive PCR on 08 August 2011. Chest x-ray findings were negative for pneumonia. Corrective treatments consisted of Azithromycin starting on 08 August 2011 for four days. The subject was not hospitalized. At the time of final contact on 11 August 2011, the subject's cough was still persisting. The duration of the cough was reported at that time as 28 days. According to the investigator, this case was epidemiologically linked to a laboratory confirmed case. Investigator causality assessment is not required as per protocol. Documents held by sender: None.
Patient had a fever of 102 F for 4 days (even after treating with acetaminophen). Patient had swollen lymph nodes behind ears, on neck and under armpits the size of lima beans (as described by patient) in addition to severe body aches. Patient visited urgent care on 11/16/2021 which they referred him to go to the emergency room which the patient did go to the same date as urgent care visit.  All tests for infection came back negative. Patient felt better on 11/17/2021, but did not feel 100% himself until 11/18/2021. .